Kornimate/medical-research-clean huggingface dataset:
safety, biodistribution, radiation dosimetry and pharmacokinetics study of bay88-8223 in japanese patients

Conditions: Prostatic Neoplasms

Summary: this is an uncontrolled, open-label, non-randomized phase i study to investigate safety, biodistribution, radiation dosimetry and pharmacokinetics of a single dose of bay88-8223 in japanese patients with castration-resistant prostate cancer and bone metastases.


Eligibility criteria:
inclusion criteria: * male ≥ 20 years of age * histologically or cytologically confirmed adenocarcinoma of the prostate * presents with at least 2 bone metastases, confirmed by scintigraphic imaging within the previous 4 weeks * patients who has failed initial hormonal therapy using either an orchiectomy or a gonadotropin releasing hormone (gnrh) agonist in combination with an antiandrogen must first progress through antiandrogen withdrawal prior to being eligible. the minimum timeframe to document failure of anti-androgen withdrawal will be four weeks * progressive castration resistant metastatic disease * castrate level of testosterone (\<50 ng/dl), treatment to maintain castrate levels of testosterone must be continued exclusion criteria: * has received an investigational drug in the 4 weeks before or is scheduled to receiving one during or in the 8 weeks after study drug administration. * has received chemo-, immuno-, or radiotherapy within the last 4 weeks prior to entry in the study, or has not recovered from acute adverse events as a result of such therapy * has received prior hemibody external radiotherapy * has a need for immediate external radiotherapy * has received systemic radiotherapy with radium-223, strontium-89, samarium-153, rhenium-186 or rhenium-188 for the treatment of bony metastases within the last 24 weeks prior to administration of study drug * when receiving bisphosphonates, has changed the dose within 4 weeks before administration of study drug

Keywords: bay88-8223 radium-223 dichloride prostate cancer
screening of fabry disease in portuguese patients with idiopathic cardiomyopathies

Conditions: Fabry Disease

Summary: in portugal, the prevalence of fabry disease is largely unknown as recently has been stressed by the portuguese hypertrophic cardiomyopathy registry investigators. on the other hand, few data on fabry screening protocols in patients with compromised ejection fraction including burned-out hypertrophic cardiomyopathy series have been published. this project intends to perform screening of fabry disease in patients with distinct cardiomyopathy phenotypes of unknown or dubious etiology and explore the less knew impact of the disease in other cardiac phenotypes.


Eligibility criteria:
inclusion criteria: patients with heart disease diagnosed after the age of 30: * unexplained hypertrophic cardiomyopathy (group a) * unexplained left ventricle hypertrophy confirmed in two different examinations using the same or different imaging methods (group b) * unexplained burned-out hypertrophic cardiomyopathy (group c) * unexplained dilated cardiomyopathy with evidence of late gadolinium enhancement involving the basal posterolateral wall segments (group d) exclusion criteria: * previous exclusion of fabry disease * previous identified causal pathogenic/likely pathogenic genetic variant * evidence of cardiomyopathy under the age of 30

Keywords: idiopathic cardiomyopathies
circulating micrornas in understanding pathogenesis of systemic lupus erythematosis

Conditions: Systemic Lupus Erythematosis

Summary: this study aims to identify the expression signature of mir-181a, mir-196a and mir-21 in plasma of sle patients and difference in their expression among groups with different systemic lupus erythematosis disease activity index (sledai) scores.


Eligibility criteria:
inclusion criteria: * adult systemic lupus erythematosis patients exclusion criteria: * patients younger than 18 years, patients with other autoimmune diseases or malignancy.
patients' and caregivers' views of multidimensional care in amyotropic lateral sclerosis in germany

Conditions: Amyotrophic Lateral Sclerosis

Summary: the progressive loss of physical functioning resulting from als leads also to high psychosocial burden for those affected, and organizational challenges related to medical care and aids. a multidimensional and -professional care is advised in order to meet the complex requirements of this disease. in germany, medical care structures may not fulfil these high requirements, since non-medical services such as psychological support or social counselling are not regularly included in care procedures for als patients. specialised palliative care is not a standard and still commonly restricted to the last weeks of life. additionally, it is well known that caregivers of als patients are highly burdened, but there is a lack of support services for them. by means of a cross-sectional, multicentre survey, we aim to investigate patients' and caregivers' perception of medical care for als, provided in germany - with particular regard to psychosocial and palliative aspects. the extent to which physical, psychological, social, spiritual, practical and informational needs are subjectively met will be assessed and correlations with mental wellbeing, subjective quality of life, attitudes towards life-sustaining measures and physician-assisted suicide, as well as caregiver burden will be examined. currently, study planning (questionnaires and ethical approval) is already completed and recruitment was started. the study aims to recruit 500 participants from nationwide als-centres. cooperating als-centres will be recruited via the german network for motoneuron diseases (mnd-net), of which our centre is a member. it is intended to provide data-based starting points on how care of als patients and their caregivers can be improved in germany, in line with their needs.


Eligibility criteria:
inclusion criteria: * patients with at least "possible als" according to el-escorial-criteria * at least 18 years old * no impairments of behaviour or mental performance relevant to everyday life that limits the ability to make judgments or give consent (e.g. as part of a comorbid ftd) exclusion criteria: * impairments of behaviour or mental performance relevant to everyday life that limits the ability to make judgments or give consent (e.g. as part of a comorbid ftd)

Keywords: palliative care caregiver burden multidimensional care
serum thyroid function after iodinated contrast administration

Conditions: Thyroid Dysfunction

Summary: this study investigated the changes in serum thyroid function and urinary iodine levels before and after the use of iodinated contrast to analyze the prevalence of thyroid dysfunction in the chinese euthyroid adults after using iodinated contrast.

this study aims to monitor the thyroid function, urinary iodine level, and other indicators of patients after using iodine contrast agents, in order to analyze the prevalence of thyroid dysfunction after using iodine containing contrast agents, and investigate the impact of different iodine contrast agents on thyroid function, in order to provide evidence for the use of iodine contrast agents in clinical practice and the risk prevention of subsequent thyroid diseases.

Eligibility criteria:
inclusion criteria: * patients who use iodinated contrast agent exclusion criteria: * patients with the following diseases: malignant tumor, critical illness (admitted to icu), mental disease, hypothalamus-pituitary disease. * administration of anti-thyroid drugs (methimazole, propylthiouracil), levothyroxine, compound iodine solution, amiodarone, immunostaining point inhibitor, tyrosine kinase inhibitor, interferon, interleukin-6, lithium, glucocorticoids β receptor blockers, dopamine, dobutamine, bromocriptine, octreotide, phenobarbital, phenytoin sodium, rifampicin, and carbamazepine within the past 6 months
the effect of bathing and moisturizers on skin hydration in atopic dermatitis: an in vivo study

Conditions: Dermatitis, Atopic

Summary: the purpose of this study is to determine the hydration effect of various regimens of skin bathing and moisturizer application on atopic dermatitis


Eligibility criteria:
inclusion criteria: * male or female; * age range 18-45 years; * subjects have history and physical findings consistent with mild to moderate ad with scorad score ≤ 40; * stop using some drugs such as oral corticosteroid for at least 4 weeks, topical corticosteroid and calcineurin inhibitor for at least 2 weeks, food supplement such as evening primrose oil, wheat extract flax seed oil sunflowerseed oil, borage oil and fish oil for at least 3 months; * subjects who have signed the written informed consent. exclusion criteria: * subjects who have medical histories such as zinc or essential fatty acid deficiency, end stage renal disease, hypothyroidism, human immunodeficiency virus (hiv), malignancies, obstructive biliary disease, diabetes mellitus and in those who have had radiation or other medical histories that may interfere the outcome; * subjects who ingest drugs that could interfere with the study results such as diuretics, antiandrogens, lipid reducing agents, isotretinoin cimetidine; * subjects cannot enroll until the end of the project; * subjects who have allergy to any ingredient in the moisturizer or cleanser that will be used in the protocol; * pregnant woman or lactating woman.

Keywords: atopic dermatitis, skin cleansing, cleanser, moisturizer, skin hydration
anti-tumor necrosis factor (tnf) treatments, work productivity and quality of life in crohn's disease

Conditions: Crohn's Disease

Summary: this multicenter, prospective, post marketing observational study (pmos) was designed to demonstrate long-term effects of anti-tumor necrosis factor therapies on work productivity and impairment scales in participants with moderate to severe crohn's disease (cd) under routine conditions. secondary objectives of this study were long-term improvement of quality of life (qol), evaluation of improvement of extraintestinal symptoms and comorbidities, and evaluation of safety.

male or female participants between 18 - 65 years of age with moderate to severe cd for whom the treating physician had recently initiated an anti-tnf treatment were included in this study. anti-tnf treatments were administered according to the treating physician's decision and applicable product label in turkey. no interventions were made to the treatment and the participant discontinuance or to the follow-up decisions of the treating physician. enrolled participants were observed for one year.

Eligibility criteria:
inclusion criteria: * male or female participants between 18-65 years of age with moderately to severely (crohn's disease activity index 220-450) active crohn's disease with or without fistula formation * participants who were able to provide authorization to use and disclose information related to the study * proven diagnosis of crohn's disease in accordance with international diagnostic criteria such as european crohn's and colitis organization (ecco) guidelines * participants for whom the physician had initiated anti-tumor necrosis factor treatment in accordance with turkish ministry of health regulations and reimbursements exclusion criteria: * participants who had a history of any kind of biological therapy and/or anti-tumor necrosis factor treatments for crohn's disease or other indications * participants who had septic complications (active infection and/or active tuberculosis (tb), undrained abscess) * participants who had bowel obstructions and fibrotic strictures * participants who had received any investigational drug within 30 days prior to the visit 1 at baseline * for any reason, participants who were considered by the investigator to be unsuitable

Keywords: crohn's disease
digital physiotherapy practice in long covid-19 patients

Conditions: Long COVID-19 Syndrome

Summary: the covid-19 can cause important sequels in the respiratory system by bilateral pneumonia and frequently presents loss of strength, dyspnea, polyneuropathies and multi-organic affectation. long covid-19 has been defined as the condition occurring in individuals with a history of probable or confirmed sars-cov-2 infection, with related symptoms lasting at least 2 months and not explainable by an alternative diagnosis. the practice of digital physiotherapy presents itself as a promising complementary treatment method to standard physiotherapy, playing a key role in the recovery of function in subjects who have passed the disease and who maintain some symptomatology over time. the aims of this research are to explore the effect of a digital physiotherapy intervention on functional recovery in patients diagnosed with long covid-19 and to identify the level of adherence to the treatment carried out. physiotherapy interventions acquires a fundamental role in the recovery of the functions and the quality of life. as secondary objectives, the aim is to identify the satisfaction and perception of patients with the intervention and the presence of barriers to its implementation (throught a qualitative research), as well as to evaluate the cost-effectiveness from the perspective of the health system. a quasi-experimental pre-post study assessed initially and at the end of the 4-week intervention the functional capacity (1-min sts and sppb) and the adherence (software). the hypothesis of this research is that the implementation of a tr program presents positive results. if hypothesis is confirmed, that would be an opportunity to define new policies and interventions to address this disease and its consequences.

the authors hypothesised that the implementation of a digital physiotherapy intervention in long covid-19 participants is effective to improve the functional capacity and adherence and have positive results in patients satisfaction.

Eligibility criteria:
inclusion criteria: * adult over 18 years old * diagnosis: long covid-19 syndrome * residing in the andalusian community during the research period * to have a computer technology with an internet connection aat home (personal computer, laptop, tablet or smartphone) * ability and knowledge to access email or whatsapp exclusion criteria: -cognitive ability not suitable for the use of technological tools

Keywords: digital physiotherapy practice (telerehabilitation) covid19 sequelae
tomosynthesis in the oslo breast cancer screening program

Conditions: Recall Rate; Cancer Detection Rate; False Positive Rate; Positive Predictive Value

Summary: the digital breast tomosynthesis (dbt) in the oslo mammography screening program will include women aged 50 to 69 years invited to the population-based mammography-screening program. all women attending the screening unit will be asked if they want to attend the trial. if so, they will be informed about the project, the technique, and the additional compression and radiation dose. all mammographic examinations of women attending the trial will be independently interpreted by four radiologists. since the trial is part of the official norwegian breast cancer screening program (nbcsp), the interpretations will be carried out on-line into the national screening database of the nbcsp. the study will include independent reading of conventional digital (2d) mammograms, 2d plus computer-aided detection (cad), 2d plus dbt, and synthetic 2d plus dbt. there will be a common consensus meeting for all examinations having a positive score. recalls and diagnostic work-up will be according to daily practice at the oslo university hospital ullevaal and the guidelines of the nbcsp. outcome measures will use performance indicators for organized screening programs, including recall rate, false positive scores, cancer detection rate, positive predictive values, and cancer characteristics for the individual readers of the trial.


Eligibility criteria:
inclusion criteria: * women 50 to 69 years who have signed the informed consent exclusion criteria: * women with pacemaker, implants, and severely disabled

Keywords: breast cancer computer-aided detection mammography screening digital breast tomosynthesis
analysis of telmisartan administered with antiretroviral therapy (art) in patients with acute hiv infection

Conditions: Acute HIV Infection; HIV Infections

Summary: this research project will study whether the drug telmisartan administered in conjunction with antiretroviral therapy (art) will help reduce nervous system infection with hiv. the investigators are studying the effect of this treatment in people who have contracted hiv infection within the past three weeks, and thus have a form of hiv called acute hiv infection. the investigators will measure biological markers of immune activation in the blood and cerebrospinal fluid to see if telmisartan may reduce the spread of hiv reservoirs in affected patients.

note regarding the primary purpose of the study: in the study design section, this protocol is classified as "other", since it is specifically designed to examine the effect of telmisartan administered in conjunction with art on the size of hiv reservoirs in the central nervous system.

Eligibility criteria:
inclusion criteria: * age ≥ 18 years old * have protocol-defined acute hiv-1 infection * be part of the search 010/rv 254 study in bangkok, thailand * ability and willingness to start art immediately after diagnosis * availability for follow-up for the duration of the planned study * systolic blood pressure ≥ 110 mmhg * agree to undergo lumbar puncture at weeks 0, 48 and 72 * ability and willingness to provide informed consent. subjects must understand the study and sign the consent form. persons who cannot read will have the consent form read to them by a member of the study staff and may then give informed consent by using making a thumb print. exclusion criteria: * pregnancy (current or within the last 6 months) or breastfeeding * uncontrolled hypertension * use of thiazolidinediones or other angiotensin receptor blockers class \[losartan, irbesartan, olmesartan, valsartan, candesartan (washout permitted)\] * screening laboratory values: absolute neutrophil count \< 750 cells/mm3, hemoglobin \<10 gm/dl creatinine clearance \<30 ml/min (estimated by the cockcroft-gault equation using ideal body weight) * known renal artery stenosis * known cirrhosis or severe liver disease * unstable coronary artery disease/angina or decompensated congestive heart failure * any history of intolerance to any angiotensin receptor blocker * need for ongoing potassium supplementation * any contraindication to lumbar puncture such as history of bleeding diathesis or cerebral mass lesion

Keywords: acute hiv infection central nervous system antiretroviral therapy telmisartan cerebrospinal fluid
project flux contact-covid-19 faculty of medicine paris-saclay

Conditions: Covid19

Summary: the worldwide health system has been marked by the sars-cov-2 pandemic. french educational system has been upset, especially medical schools, which, because of their hospital location, are particularly exposed to the spread of the virus. the medical school of paris-saclay university, located within bicetre university hospital, ap-hp, must therefore adapt on a daily basis to ensure educational continuity. taking advantage of an exceptional scientific ecosystem, innovative viral epidemic propagation modeling approaches based on both simulation and contact tracing data will be tested in real-life conditions. these propagation models will serve to scientifically optimize future educational organization procedures in this medical school.

all the participants will be equipped with individual wireless contact tracing technology. anonymised contact events will be automatically monitored for a period of two months to measure the daily contact flow density between the students at medical school. epidemic simulation models will be enriched with these real contact tracing data to generate optimized viral propagation probability networks. during the same period, co2 measurement will be performed in several relevant sectors (classrooms, amphitheaters, corridors etc) to allow a more holistic understanding of the propagation conditions. finally, the probabilistic models will be confronted to the results of a two step covid-19 screening campaign.

Eligibility criteria:
inclusion criteria: * volunteers of adult men and women over 18 from the paris-saclay medicine ufr * belonging to the teaching staff * belonging to the promotions of dfgsm 2 and 3, and dfasm 1 and 2 (2nd to 5th year of medical study) * administrative staff * affiliated to a social security scheme or beneficiary (excluding ame) * informed and written consent exclusion criteria: * absence of intercurrent disease before inclusion * positive antigenic or pcr test at the time of inclusion

Keywords: simulation epidemiology public health computer science infectiology technology pandemic covid
nasogastric tube in premature babies - pain and treatment

Conditions: Infant, Premature

Summary: does sucrose or pacifier influence pain in premature babies when a nasogastric tube is inserted?

a total of 24 premature babies are randomised to receive either placebo (sterile water), 30 % sucrose, or pacifier in a complete factorial, cross-over design. pain is rated on the pipp scale by observers blinded to the procedure other than use of pacifier.

Eligibility criteria:
inclusion criteria: * 28 - 32 weeks gestational weeks * not on mechanical ventilation exclusion criteria: * high risk group regarding cerebral prognosis

Keywords: pain infant, premature intubation, gastrointestinal neonatal nursing
kinetics and ecology of human papillomavirus genital infections in young women

Conditions: HPV Genital Infection (Primary Condition Studied); Bacterial Vaginosis; Chlamydiae Infection

Summary: most genital infections by human papillomaviruses (hpv) are asymptomatic or benign and clear within a few months or years. there infections are much less studies than chronic infections, even though they represent the main reservoir for the virus. the goal of this project is to decipher the kinetics of the virus and of the host immune response in acute hpv genital infections in your women. this will be performed by following women longitudinally and regularly in order to measure variations in virus load, immune cell count, cytokine concentration and antibody titers. the investigators will also investigate the interaction between these kinetics and host genetics and host vaginal microbiota


Eligibility criteria:
inclusion criteria: * sexually active with at least one new partner over the last 12 months * subjects must be able and willing to give written informed consent * living in the 'agglomération de montpellier' exclusion criteria: * history of cervical pathology * pregnant or intending to become pregnant soon (in the coming year) * infected by hiv * undergoing (or planning to undergo) heavy treatment (biotherapy, chemotherapy, immunosuppression) * participation in a clinical trial involving administration of drugswithin the last 4 weeks before the screening date

Keywords: human papillomaviruses clearance kinetics ecology bacterial vaginosis immune response microbiota